Effect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis Optica

Figure 5

Complement markers are unchanged in NMO rats treated with CXCR2 antagonist, SCH527123. C4d, a marker for activation of the classical complement pathway, showed similar staining patterns in and around spinal cord lesions from rats treated with SCH527123 compared to vehicle control, quantified (a) with a representative sample (b). Depo-Medrol at 10 mg/kg showed lower levels of C4d staining. Staining with anti-C5-C9 was used to assess overall terminal activation of complement pathways. C5-C9 was not significantly different among the three groups, quantified (c) with a representative sample (d).

(a)

(b)

(c)

(d)